바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 위암센터, 고난도암수술팀, 고난도암수술팀

전문진료분야

  • <종양내과> 위암, 신장암, 방광암, 육종, 항암약물치료, 조기임상신약치료

교육 및 임상 경력

  • 1990.03-1991.02  세브란스  병원  인턴
  • 1991.03-1995.02  세브란스  병원  내과  전공의(내과  전문의)
  • 1995.03-1998.07  연세대  의대  내과학교실,  암센터  전임의  (혈액종양내과  전문의)
  • 1998.08-2000.07  미국  텍사스  주립대학  부속  의과대학  암센터(Cancer  Therapy  and  Research  Center)의  전임의  (clinical  and  research  fellow)
  • 2001.03-2006.02  연세대학교  의과대학  암전이연구센터  조교수
  • 2006.03-2007.02  연세대학교  의과대학  암전이연구센터  부교수
  • 2008.03-2011.02  연세대학교  의과대학  종양내과  부교수 
  • 2009.03-2010.06  암전이연구센터  중개연구실장
  • 2009.03-2013.02  연세의료원  암센터  종양내과  과장
  • 2009.06-현        재  세브란스병원  피험자보호센터  소장
  • 2009.03-현        재  대한  항암요법  연구회  비뇨/부인암  분과장
  • 2011.03-현        재  연세대학교  의과대학  내과학교실  종양내과  교수

학술관련경력

  • 대한내과학회 학술위원
  • 대한 암학회 이사
  • 미국암학회(ASCO) 정회원
  • 국암연구학회(AACR) 정회원
  • 한국임상암학회 국제협력위원회 위원장
  • 대한 위암학회 학술위원 및 보험 위원
  • 건강보험심사평가원 진료심사평가위원
  • 한국의약품안전관리원 안전성평가 전문위원회 전문위원
  • 임상평가 소분과 위원
  • 중앙약사심의위원회 위원
  • KoNect 학술위원
  • *수상경력
  • 2005 우수 논문 수상 의학, 서울, 한국의 연세 대학
  • 2006 우수 수행 수상, 연세 대학교
  • 2008 우수 연구 논문상(과학 기술 사회의 한국 연맹)
  • 2012 2012학년 연세대학교 우수연구실적 표창

주요 관심분야

  • 위암의 항암약물치료, 신약 임상연구

학력사항

  • 1990 연세대학교 의과대학 학사
  • 1994 연세대학교 의과대학 석사
  • 1997 연세대학교 의과대학 박사
  • 1998 미국 의사 자격 획득

논문

  • 1. A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK, Chung HC.Oncology. 2006 Jan 27;70(1):63-70.
  • 2. Intermediate dose 5-Fluorouracil-induced encephalopathy. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC.Jpn J ClinOncol. 2006 Jan;36(1):55-9.
  • 3. Systematic analysis of cDNA microarray-based CGH. Park CH , Jeong HJ , Choi YH , Kim SC , Jeong
  • HC , Park KH , Lee GY , Kim TS, Yang SW, Ahn SW, Kim YS, Rha SY, Chung HC. Int J Mol Med. 2006 Feb;17(2):261-7.
  • 4. Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. Rha SY, Jeung HC, Yang WI, Kim JJ, Oh TJ, An SW, Chung HC. Oncol Rep. 2006 Apr;15(4):749-55.
  • 5. Ribonucleotidereductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC. Pharmacogenet Genomics. 2006 Jun;16(6):429-38.
  • 6. Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. Cho NH, Choi YP, Moon DS, Kim H, Kang S, Ding O, Rha SY, Yang YJ, Cho SH. Cancer Science 2006;97(10):1082-92
  • 7. Activation of Hypoxia-Inducible Factor-1{alpha} isnecessary for Lysophosphatidic Acid-induced VEGFexpression. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK, Han JW, Lee HY. Clin Cancer Res. 2006 Nov 1;12(21):6351-8.
  • 8. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. British J Cancer 2006 :95:1637-41
  • 9. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT. Cancer ChemotherPharmacol. 2007 Feb;59(3):295-300
  • 10. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Jeung HC, Rha SY, Noh SH, Roh JK, Chung HC.Cancer ChemotherPharmacol. 2007:59:313
  • 11. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q. Oncogene. 2007 8;26(6):934-44.
  • 12. A comparative study of volumetric analysis, histopathologicdownstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Kim NK, Baik SH, Min BS, Pyo HR, Choi YJ, Kim H, Seong J, Keum KC, Rha SY, Chung HC. Int J RadiatOncolBiol Phys. 2007:67:204-10
  • 13. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, Noh SH, Chung HC. J SurgOncol. 2007: 95(6):461-8.
  • 14. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK. Cancer ChemotherPharmacol. 2007 Mar 21
  • 15. Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Lyu CJ, Rha SY, Won SC. Yonsei Med J. 2007 Apr 30;48(2):171-5.
  • 16. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Yang S, Jeung HC, Jeong HJ, Choi YH, Kim JE, Jung JJ, Rha SY, Yang WI, Chung HC. Genomics. 2007 Apr;89(4):451-9
  • 17. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Chan SL, Cui Y, van Hasselt A, Li H, Srivastava G, Jin H, Ng KM, Wang Y, Lee KY, Tsao GS, Zhong S, Robertson KD, Rha SY, Chan AT, Tao Q. Lab Invest. 2007, 87(7):644-50
  • 18. Cetuximabrescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Pyo JY, Roh JK. ActaOncol. 2007;46(4):547-9.
  • 19. Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC. Oncologist. 2007 May;12(5):543-54.
  • 20. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Baik SH, Kim NK, Lee CH, Lee KY, Sohn SK, Cho CH, Kim H, Pyo HR, Rha SY, Chung HC. Surg Today. 2007 May;37(6):455-9.
  • 21. Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. Kang SH, Park CH, Jeung HC, Kim KY, Rha SY, Chung HC. Int J Mol Med. 2007 Jun;19(6):901-8.
  • 22. Novel and simple transformation algorithm for combining microarray data sets.
  • Kim KY, Ki DH, Jeong HJ, Jeung HC, Chung HC, Rha SY. BMC Bioinformatics. 2007 Jun 25;8:218.
  • 23. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, Roh JK, Chung HC. Oncologist. 2007 Jun;12(6):622-30.
  • 24. Bilateral Breast Cancer: Differential Diagnosis Using Histological and Biological Parameters. Gong SJ, Rha SY, Jeung HC, Roh JK, Yang WI, Chung HC. Jpn J ClinOncol. 2007 Jul: 37(7):487-92
  • 25. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Moon YW, Jeung HC, Rha SY, Choi YH, Yang WI, Chung HC. Breast Cancer Res Treat. 2007 Jul;104(1):31-7.
  • 26. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. Br J Cancer. 2007 Aug 20, 97(4):458-63
  • 27. Molecular basis of the differences between normal and tumor tissues of gastric cancer. Yang S, Shin J, Park KH, Jeung HC, Rha SY, Noh SH, Yang WI, Chung HC.BiochimBiophysActa. 2007 Sep, 1772(9):1033-40.
  • 28. Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. JJ Jung, HC Jeung, JO Lee, TS Kim, HC Chung, SY Rha. Oncology Reports 2007 Sep: 18(3):593-599
  • 29. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic
  • hybridization. GY Lee, WI Yang, HC Jeung, SC Kim, MY Seo, CH Park, HC Chung, SY Rha. BMC Genomics 2007 Sep 3; 8(1):305
  • 30. Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute. Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Ann SurgOncol. 2007 Oct: 14(10):2730-7
  • 31. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. DH Ki, HC Jeung, CH Park, SH Kang, GY Lee, WS Lee, NK Kim, HC Chung, SY Rha. Int J Cancer 2007 Nov 1: 121 (9) 2005-12.
  • 32. Entropy-based analysis of non-linear relationship between gene expression profiles of amplified and non-amplified RNA. JH Shin, CH Park, YJ Yang, SC Kim, MY Seo, SH Yang, SB Cho, HC Chung, SY Rha.Int J Mol Med 2007 Dec;20(6):905-12.
  • 33. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Yoon KT, Kim JK, Kim Do Y, Ahn SH, Lee JD, Yun M, Rha SY, Chon CY, Han KH. Oncology. 2007 Dec;72Suppl 1:104-10
  • 34. Direct integration of microarrays for selecting informative genes and phenotype classification Y Yoon, J Lee, S Park, S Bien, HC Chung, SY Rha. Information Sciences 2008 Jan:178: 88-105
  • 35. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC. Cancer ChemotherPharmacol. 2008 Jan;61(1):157-65.
  • 36. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. CK Im, HC Jeung, SY Rha, NC Yoo, SH Noh, JK Roh, HC Chung, Cancer ChemotherPharmacol 2008 Feb;61(2):315-21.
  • 37. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J. Breast Cancer Res Treat. 2008 Mar;108(2):241-50.
  • 38. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylicpolyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, Min JS, Kim BS, Chung HC. Ann Oncol. 2008 Mar;19(3):520-6.
  • 39. S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. Jung JY, Rha SY, Ahn JB, Yang WI, Noh SH, Chung HC, Jeung HC. Korean J Intern Med. 2008 Mar;23(1):37-41.
  • 40. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. J Jeong, HC Jeung, SY Rha, CK Im, SJ Shin, JB Ahn, SH Noh, JK Roh and HC Chung. Ann Oncol. 2008 Jun;19(6):1135-40
  • 41. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC. Ann Oncol. 2008 Jun;19(6):1146-53.
  • 42. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Choi HJ, Kim NK, Keum KC, Cheon SH, Shin SJ, Baik SH, Choen JH, Rha SY, Roh JK, Jeung HC, Chung HC, Ahn JB. RadiotherOncol. 2008 Jun;87(3):361-6
  • 43. Variation of the 3' telomeric overhang lengths in human cells. Lee ME, Rha SY, Jeung HC, Kim TS, Chung HC, Oh BK. Cancer Lett. 2008 Jun 8;264(1):107-118.
  • 44. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Cancer Res. 2008 Jun 1;68(11):4277-86.
  • 45. Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. Kim KY, Ki DH, Jeung HC, Chung HC, Rha SY. BMC Bioinformatics. 2008 Jun 16;9:283.
  • 46. SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. Yoo J, Lee Y, Kim Y, Rha SY, Kim Y. BMC Bioinformatics. 2008 Jun 23;9:290.
  • 47. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, Loyo M, Chan AT, Srivastava G, Tsao GS, Sellar GC, Sung JJ, Sidransky D, Tao Q.PLoS ONE. 2008 Aug 20;3(8):e2990.
  • 48. Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma Yu EJ, Lee Y, Rha SY, Kim TS, Chung HC, Oh BK, Yang WI, Noh SH, Jeung HC. Mol Cancer Res. 2008 Oct;6(10):1554-66.
  • 49. Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Shin SJ, Jeung HC, Ahn JB, Rha SY, Yoo NC, Roh JK, Noh SH, Chung HC. Cancer Lett. 2008 Nov 8;270(2):269-76
  • 50. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. Min BS, Choi YJ, Pyo HR, Kim H, Seong J, Chung HC, Rha SY, Kim NK. Arch Surg. 2008 Nov;143(11):1091-7
  • 51. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, Noh SH, Rha SY.Genomics. 2009 Jan;93(1):52-61.
  • 52. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Yu J, Tao Q, Cheng YY, Lee KY, Ng SS, Cheung KF, Tian L, Rha SY, Neumann U, Rocken C, Ebert MP, Chan FK, Sung JJ. Cancer. 2009 Jan 1;115(1):49-60.
  • 53. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC. 2009 Feb;20(2):272-7.
  • 54. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Ying J, Poon FF, Yu J, Geng H, Wong AH, Qiu GH, Goh HK, Rha SY, Tian L, Chan AT, Sung JJ, Tao Q. Br J Cancer. 2009 Feb:100(4):663-9.
  • 55. Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. Oh SJ, Hyung WJ, Song J, Rha SY, Chung HC, Choi SH, Noh SH. J GastroenterolHepatol. 2009 Mar;24(3):475-9
  • 56. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Noh SH, Chung HC.Cancer Lett. 2009 Mar 18: 277(2):155-63
  • 57. Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. Jeung HC, Rha SY, Park CH, Im CK, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. Int J Oncol. 2009 Mar 34(3):787-96.
  • 58. Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. Rha SY, Jeung HC, Seo MY, Kim SC, Yang WI, Moon YW, Chung HC. Int J Oncol. 2009 Mar;34(3):837-46.
  • 59. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, Chung HC, Choi SH, Noh SH; J SurgOncol. 2009 Apr 1:99(5):275-80
  • 60. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, Noh SH, Chung HC. Cancer ChemotherPharmacol. 2009 Apr;63(5):919-27.
  • 61. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. HR Kim, SY Rha, SH Cheon, JK Roh, YN Park, NCYoo, Annals Oncol 2009 Apr:20(4):780-7.
  • 62. Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. Park S, Shin SJ, Ahn JB, Jeung HC, Rha SY, Lee SK, Chung HC. Yonsei Med J. 2009 Apr 30;50(2):296-9.
  • 63. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY.Cancer Res Treat. 2009 Jun;41(2):67-72.
  • 64. Prognosis of pN3 Stage Gastric Cancer. Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY.Cancer Res Treat. 2009 Jun;41(2):73-9.
  • 65. Prediction of recurrence of early gastric cancer after curative resection. Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, Rha SY, Chung HC, Choi SH, Wang LB, Noh SH. Ann SurgOncol. 2009 Jul:16(7):1896-902.
  • 66. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Hu XT, Zhang FB, Fan YC, Shu XS, Wong AH, Zhou W, Shi QL, Tang HM, Fu L, Guan XY, Rha SY, Tao Q, He C. Oncogene. 2009 Jul 2:28(6):2466-75.
  • 67. Subtelomeric DNA methylation and telomere length in human cancer cells.Lee ME, Rha SY, Jeung HC, Chung HC, Oh BK. Cancer Lett. 2009 Aug 18;281(1):82-91.
  • 68. Prognostic index reflecting genetic alteration related to disease-free time for gastric cancer patient. Kim M, Rha SY. Oncol Rep. 2009 Aug;22(2):421-31.
  • 69. A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. Ki-Yeol Kim1, Hyun Cheol Chung2, 3, 4 and Sun Young Rha. Journal of Bioscience and Bioengineering 2009 Sep:108:252-258
  • 70. Clinical value of ezrin expression in primary osteosarcoma. Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY. Cancer Res Treat. 2009 Sep;41(3):138-44.
  • 71. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, Chung HC, Ganesan K, So J, Soo KC, Lim D, Chan WH, Wong WK, Bowtell D, Yeoh KG, Grabsch H, Boussioutas A, Tan P. PLoS Genet. 2009 Oct;5(10):e1000676
  • 72. Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. Moon YW, Rha SY, Zhang X, Jeung HC, Yang WI, Kwon O, Jeong JH, Cheon SH, Yoo NC, Chung HC. J SurgOncol. 2009 Nov 1:100(6): 459-65
  • 73. Identification of significant regional genetic variations using continuous CNV values in aCGH data.
  • Kim KY, Lee GY, Kim J, Jeung HC, Chung HC, Rha SY. Genomics. 2009 Nov: 94(5):317-23
  • 74. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Cancer ChemotherPharmacol. 2009 Dec: 65(1):167-75
  • 75.Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, An JR, Noh SH, Chung HC, Jeung HC. Cancer Res Treat. 2009 Dec;41(4):196-204.
  • 76. A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. Im CK, Rha SY, Jeung HC, Jeong J, Lee SH, Noh SH, Roh JK, Chung HC.Oncology. 2009;77(6):349-57.
  • 77. Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC.Jpn J ClinOncol. 2010 Jan;40(1):29-35.
  • 78. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Chang H, Rha SY, Jeung HC, Im CK, Noh SH, Kim JJ, Chung HC.Oncol Rep. 2010 Jan;23(1):271-8.
  • 79. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, Park KH, Noh SH, Roh JK, Chung HC.Cancer Lett. 2010 Feb 1;288(1):124-32
  • 80. A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. Im CK, Rha SY, Jeung HC, Ahn JB, Shin SJ, Noh SH, Roh JK, Chung HC.
  • Am J ClinOncol. 2010 Feb;33(1):56-60.
  • 81. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators.
  • Moon YW, Rha SY, Shin SJ, Chang H, Shim HS, Roh JK. J Cancer Res ClinOncol. 2010 Mar;136(3):387-94
  • 82. The clinical significance of ascetic fluid CEA in advanced gastric cancer with ascites. M Jung, HC Jeung, SS Lee, JY Park, S Kong, SH Lee, SH Noh, HC Chung, SY Rha. J Cancer Res ClinOncol. 2010 Apr;136(4):517-26
  • 83. Green tea consumption and stomach cancer risk: a meta-analysis. Kang H, Rha SY, Oh KW, Nam CM. Epidemiol Health. 2010 Apr 26;32:e2010001.
  • 84. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Choen JH, Jeung HC, Rha SY, Roh JK, Chung HC, Ahn JB. RadiotherOncol. 2010 Jun;95(3):303-7
  • 85. Wernicke's Encephalopathy in Advanced Gastric Cancer. Jung ES, Kwon O, Lee SH, Lee KB, Kim JH, Yoon SH, Kim GM, Jeung HC, Rha SY.Cancer Res Treat. 2010 Jun;42(2):77-81.
  • 86. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. HR Kim, SH Cheon, K Lee, JR Ahn, HC Jeung, SS Lee, HC Chung, SH Noh, SY Rha.Int J Hyperthermia 2010 June; 26(4):305-315 (2.412)
  • 87. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, Chang H, Roh JK, Noh SH, Kim BS, Chung HC. Cancer ChemotherPharmacol. 2010 Sep;66(4):797-805
  • 88. Kidney Cancer Working Group report. Naito S, Tomita Y, Rha SY, Uemura H, Oya M, Song HZ, Zhong LH, Wahid MI. Jpn J ClinOncol. 2010 Sep;40Suppl 1:i51-56.
  • 89. Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, Kim HS, Park YN, Rha SY.Cancer Res Treat. 2010 Sep;42(3):180-4.
  • 90. Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. Kim J, Lee SG, Song J, Kim SJ, Rha SY, Lee KA, Park TS, Choi JR. Cancer Genet Cytogenet. 2010 Sep;201(2):73-80.
  • 91. Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. Park CH, Rha SY, Jeung HC, Kang SH, Ki DH, Lee WS, Noh SH, Chung HC.J SurgOncol. 2010 Oct 1;102(5):454-61.
  • 92. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Shin SJ, Jeung HC, Ahn JB, Rha SY, Roh JK, Park KS, Kim DH, Kim C, Chung HC. Invest New Drugs. 2010 Oct;28(5):650-8
  • 93. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Jung JJ, Noh S, Jeung HC, Jung M, Kim TS, Noh SH, Roh JK, Chung HC, Rha SY. Cancer Sci. 2010 Oct;101(10):2200-6
  • 94. Identification of genes related to a synergistic effect of taxane and suberoylanilidehydroxamic acid combination treatment in gastric cancer cells. Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, Kwon HJ, Kim BS, Chung HC.J Cancer Res ClinOncol. 2010 Dec;136(12):1901-13
  • 95. The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. Ann SurgOncol. 2010 Dec;17(12):3259-68.
  • 96. Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. Kim JH, Rha SY, Kim C, Kim GM, Yoon SH, Kim KH, Kim MJ, Ahn JB, Chung HC, Roh JK, Kim HS. Cancer Res Treat. 2010 Dec;42(4):217-24.
  • 97. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC. Breast Cancer Res Treat. 2011 Jan;101(1):49-55.
  • 98. Brain metastases from colorectal carcinoma: prognostic factors and outcome. Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, Rha SY. J Neurooncol. 2011 Jan;101(1):49-55
  • 99. Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, Rha SY. Oncol Rep. 2011 Mar;25(3):717-27
  • 100. CD44-SLC1A2 Gene Fusions in Gastric Cancer. Tao J, Deng NT, Ramnarayanan K, Huang B, Oh HK, Leong SH, Lim SS, Tan IB, Ooi CH, Wu J, Lee M, Zhang S, Rha SY, Chung HC, Smoot DT, Ashktorab H, Kon OL, Cacheux V, Yap C, Palanisamy N, Tan P. SciTransl Med. 2011 Apr 6;3(77):77ra30.
  • 101. Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, Palanisamy N, Voorhoeve PM, Tan P. Clin Cancer Res. 2011 May 1;17(9):2657-67.
  • 102. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC. Cancer. 2011 May 15;117(10):2050-7.
  • 103. Prevalence and associated factors of psychological distress among Korean cancer patients. Kim SJ, Rha SY, Song SK, Namkoong K, Chung HC, Yoon SH, Kim GM, Kim KR. Gen Hosp Psychiatry. 2011 May-Jun;33(3):246-52.
  • 104.Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY. Oncology. 2011 Jun 14;80(1-2):107-117.
  • 105. A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. Park HS, Rha SY, Kim HS, Hyung WJ, Park JS, Chung HC, Noh SH, Jeung HC.Oncology. 2011 Jun 15;80(1-2):142-150.
  • 106. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Joo EH, Rha SY, Ahn JB, Kang HY. Support Care Cancer. 2011 Jul;19(7):971-8.
  • 107. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Gastroenterology. 2011 Aug;141(2):476-85
  • 108. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. Choi JY, Kim MJ, Park YN, Lee JM, Yoo SK, Rha SY, Seok JY. AJR Am J Roentgenol. 2011 Aug;197(2):399-405.
  • 109. Sunitinib for asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, Rha SY Oncology. 2011 Aug;80(5-6):395-405.
  • 110. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Jeung HC, Rha SY, Shin SJ, Lim SJ, Roh JK, Noh SH, Chung HC. Anticancer Drugs. 2011 Sep;22(8):801-10.
  • 111. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Kim HR, Cheon SH, Rha SY, Lee S, Han KH, Chon CY, Lee JD, Sung JS, Chung HC. Asia Pac J ClinOncol. 2011 Sep;7(3):258-69.
  • 112. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Chon HJ, Rha SY, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HC. Cancer ChemotherPharmacol. 2011 Oct;68(4):991-9
  • 113. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. J ClinOncol. 2011 Oct 20; 29(30):3968-76
  • 114. Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor. Kim YM, Shin YK, Jun HJ, Rha SY, Pyo H. J Radiat Res (Tokyo). 2011 Nov;52(6):752-65.
  • 115. MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, Rha SY. Hepatogastroenterology.2011 Nov-Dec;58(112):2015-9
  • 116. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK, Rha SY.Oncology. 2011 Dec;81(3-4):175-83.
  • 117. Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. Kim HS, Lee H, Jeung HC, Noh SH, Chung HC, Roh JK, Nam CM, Rha SY.Jpn J ClinOncol. 2011 Dec;41(12):1344-50.
  • 118. A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. Ooi CH, Oh HK, Wang HZ, Tan AL, Wu J, Lee M, Rha SY, Chung HC, Virshup DM, Tan P. PLoS Genet. 2011 Dec;7(12):e1002415.
  • 119. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC. Cancer. 2012 Feb1; 118(3): 729-39
  • 120. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Lee SS, Jeung HC, Chung HC, Noh SH, Hyung WJ, Ahn JY, Rha SY. Invest New Drugs. 2012 Feb;30(1):357-63.
  • 121. External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer. Kim JH, Kim HS, Seo WY, Nam CM, Kim KY, Jeung HC, Lai JF, Chung HC, Noh SH, Rha SY. Ann Oncol. 2012 Feb;23(2):361-7.
  • 122.An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Grunwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; on behalf of the REACT Study Group. Eur J Cancer. 2012 Feb; 48(3):324-332
  • 123.A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Lay-Keng Tan A, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. Gut. 2012 Feb 7.;61(5):673-84
  • 124. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.Cancer. 2012 Mar 1;118(5):1252-9.
  • 125. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Lee EM, Rha SY, Lee J, Park KH, Ahn JH. Cancer ChemotherPharmacol. 2012 Mar;69(3):635-42
  • 126. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. Lee S, Oh T, Chung H, Rha S, Kim C, Moon Y, Hoehn BD, Jeong D, Lee S, Kim N, Park C, Yoo M, An S. Int J Oncol. 2012 Mar;40(3):889-98
  • 127. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC.
  • Eur J Cancer. 2012 Mar;48(4):518-26.
  • 128.Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. Lee HY, Shin SJ, Kim HS, Hong SJ, Han JW, Lim ST, Roh JK, Rha SY. Cancer Res Treat. 2012 Mar;44(1):43-9.
  • 129. Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Noh S, Jung JJ, Jung M, Kim KH, Lee HY, Wang B, Cho J, Kim TS, Jeung HC, Rha SY. OncolLett. 2012 Mar;3(3):699-703.
  • 130. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH, Kim C, Chung HC. Invest New Drugs. 2012 Apr;30(2):672-80.
  • 131. Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. Roh MR, Zheng Z, Kim HS, Kwon JE, Jeung HC, Rha SY, Chung KY.ExpMolPathol. 2012 Apr;92(2):236-42.
  • 132. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CC, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, Rha SY, So J, Salto-Tellez M, Yeoh KG, Wong WK, Zhu YJ, Futreal PA, Pang B, Ruan Y, Hillmer AM, Bertrand D, Nagarajan N, Rozen S, Teh BT, Tan P. Nat Genet. 2012 May;44(5):570-4.
  • 133. Methylation Status of Lamin A/C in Gastric Cancer Cell Lines. Lee WS, Jung JJ, Jeung HC, Noh SW, Oh BK, Kim KY, Kim TS, Chung HC, Roh JK, Rha SY.Hepatogastroenterology. 2012 Jun;59(116):1313-8
  • 134. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. Ro J, Park S, Kim SB, Kim TY, Im YH, Rha SY, Chung JS, Moon H, Santillana S. BMC Cancer. 2012 Jul 28;12(1):322.
  • 135. Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. Kim HS, Kim SC, Kim SJ, Park CH, Jeung HC, Kim YB, Ahn JB, Chung HC, Rha SY. BMC Genomics. 2012 Jul 30;13:348.
  • 136. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. Invest New Drugs. 2012 Aug;30(4):1501-10.
  • 137. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.Harshman LC, Xie W, Bjarnason GA, Knox JJ, Mackenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Lancet Oncol. 2012 Sep;13(9):927-35.
  • 138. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. J ClinOncol. 2012 Sep 20;30(27):3361-7.
  • 139. A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. Park HJ, Nam EJ, Rha SY, Kim S, Kim SW, Kim JW, Kim YT. GynecolOncol. 2012 Sep;126(3):357-63.
  • 140. Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma. Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza H. Jpn J ClinOncol. 2012 Sep;42(9):836-44.
  • 141. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, Rha SY, Lee CG, Koom WS. Radiother Oncol. 2012 Sep;104(3):367-73.
  • 142. Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. PLoS One. 2012;7(9):e45127
  • 143. Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. Jung M, Kim GW, Jung I, Ahn JB, Roh JK, Rha SY, Chung HC, Kim NK, Kim TI, Shin SJ. BMC Cancer. 2012 Oct 12;12:471.
  • 144. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH. Yonsei Med J. 2012 Nov 1;53(6):1128-35.
  • 145. Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry. Lim SM, Hwang JW, Bae SK, Bae SH, Ahn JB, Rha SY, Roh JK, Chung HC, Shin SJ.
  • Anal Quant Cytol Histol. 2012 Dec;34(6):309-16.
  • 146. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha SY, Lee KB, Kang JH, Park BJ. Br J Cancer. 2013 Jan 15;108(1):39-48.
  • 147. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. Kim YB, Jeung HC, Jeong I, Lee K, Rha SY, Chung HC, Kim GE. J Radiat Res. 2013 Jan;54(1):52-60.
  • 148. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P. Gut. 2013 Jan;62(1):22-33.
  • 149. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grunwald V. Urology. 2013 Jan;81(1):143-9.
  • 150. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Invest New Drugs. 2013 Feb;31(1):1-13.
  • 151. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, Ha SJ, Soo RA, Chung KY, Kim JH, Lee JH, Shim HS, Cho BC. J Clin Oncol. 2013 Feb 20;31(6):731-7.
  • 152. Identifying genes related to radiation resistance in oral squamous cell carcinoma cell lines. Lee SY, Park HR, Cho NH, Choi YP, Rha SY, Park SW, Kim SH. Int J Oral Maxillofac Surg. 2013 Feb;42(2):169-76.
  • 153. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. Lancet Oncol. 2013 Feb;14(2):141-8.
  • 154. Characterization of naturally Epstein-Barr virus infected gastric carcinoma cell line YCCEL1. Kim DN, Seo MK, Choi H, Kim SY, Shin HJ, Yoon AR, Tao Q, Rha SY, Lee SK. J Gen Virol. 2013 Mar;94(Pt 3):497-506.
  • 155. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin--a treatment. Jung AR, Yoo JE, Shim YH, Choi YN, Jeung HC, Chung HC, Rha SY, Oh BK.
  • Anticancer Res. 2013 Mar;33(3):821-9.
  • 156. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
  • Roh MR, Zheng Z, Kim HS, Jeung HC, Rha SY, Chung KY. Melanoma Res. 2013 Apr;23(2):114-24.
  • 157. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Koh Y, Lim HY, Ahn JH, Lee JL, Rha SY, Kim YJ, Kim TM, Lee SH. Ann Oncol. 2013 Apr;24(4):1026-31.
  • 158. Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. Chang H, Rha SY, Jeung HC, Park KH, Kim TS, Kim YB, Chung HC. Int J Mol Med. 2013 May;31(5):1202-8.
  • 159. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, Roh JK, Shin SJ. J Surg Oncol. 2013 May;107(6):613-8.
  • 160. Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Kim HS, Shin SJ, Kim SC, An S, Rha SY, Ahn JB, Cho BC, Choi HJ, Sohn JH, Kim HS, Chung HC, Kim JH, Roh JK, Lee S. Support Care Cancer. 2013 Jun;21(6):1751-9.
  • 161. Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells. Lim SM, Hwang JW, Ahn JB, Bae SK, Park CH, Kim KY, Rha SY, Chung HC, Roh JK, Shin SJ. Anticancer Res. 2013 Jun;33(6):2499-508.
  • 162. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Cho BC.
  • Yonsei Med J. 2013 Jul;54(4):854-64
  • 163. The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, Riely GJ, Kim JH, Cho BC. Yonsei Med J. 2013 Jul;54(4):865-74.
  • 164. PIK3CA Mutations in Hepatocellular Carcinoma in Korea. Kim H, Park CK, Lee SJ, Rha SY, Park KH, Lim HY. Yonsei Med J. 2013 Jul;54(4):883-7
  • 165. Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. Yoon HI, Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, Rha SY, Kim KH, Koom WS. Radiother Oncol. 2013 Jul;108(1):72-7.
  • 166. Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Jung M, Choi EH, Nam CM, Rha SY, Jeung HC, Lee SH, Yang WI, Roh JK, Chung HC. Ann Surg Oncol. 2013 Aug;20(8):2615-24.
  • 167. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the international mRCC database consortium criteria. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. Cancer. 2013 Aug 15;119(16):2999-3006
  • 168. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. BMC Cancer. 2013 Aug 23;13:394.
  • 169. Changing treatment patterns in elderly patients with resectable colon cancer. Kim GM, Ahn JB, Rha SY, Kim HS, Kang B, Kim MW, Choi SY, Roh JK, Chung HC, Kim NK, Shin SJ. Asia Pac J Clin Oncol. 2013 Sep;9(3):265-72.
  • 170. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY; For the International mRCC Database Consortium. Target Oncol. 2013 Sep;8(3):203-9.
  • 171. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Lee YK, Jun HJ, Nahm JH, Lim TS, Park JS, Ahn JB, Rha SY, Chung HC, Oh HE, Song JS, Yang WI, Kim HS. Jpn J Clin Oncol. 2013 Oct;43(10):996-1003
  • 172. Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. Kim KH, Yoon SH, Lee HJ, Kim HS, Shin SJ, Ahn JB, Rha SY. Cancer Chemother Pharmacol. 2013 Oct;72(4):853-60.
  • 173. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, Rha SY. Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35.
  • 174. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. Yoo C, Lee J, Rha SY, Park KH, Kim TM, Kim YJ, Lee HJ, Lee KH, Ahn JH. Invest New Drugs. 2013 Dec;31(6):1602-8.
  • 175. A case of gingival candidiasis with bone destruction on gastric cancer patient receiving cytotoxic chemotherapy. Lim S, Kil TJ, Kim HR, Han S, Rha SY. Case Rep Oncol Med. 2014;2014:145394.
  • 176. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. Lee JS, Lim SM, Rha SY, Roh JK, Cho YJ, Shin KH, Yang WI, Kim SH, Kim HS. J Clin Pathol. 2014 Jan;67(1):33-9.
  • 177. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. Int J Oncol. 2014 Jan;44(1):5-16.
  • 178. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA. Ann Oncol. 2014 Jan;25(1):149-54.
  • 179. The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. Choi GC, Li J, Wang Y, Li L, Zhong L, Ma B, Su X, Ying J, Xiang T, Rha SY, Yu J, Sung JJ, Tsao SW, Chan AT, Tao Q. Mol Cancer Res. 2014 Feb;12(2):228-38.
  • 180. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. Eur Urol. 2014 Mar;65(3):577-84.
  • 181. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee. Eur J Cancer. 2014 Mar;50(4):746-52.
  • 182. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grunwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Lancet Oncol. 2014 Mar;15(3):286-96.
  • 183. Ifosfamide-induced Fanconi syndrome with diabetes insipidus. Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, Rha SY, Kim HS. Korean J Intern Med. 2014 Mar;29(2):246-9.
  • 184. Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. Wang Y, Choueiri TK, Lee JL, Tan MH, Rha SY, North SA, Kollmannsberger CK, McDermott DF, Heng DY. Br J Cancer. 2014 Mar 18;110(6):1433-7.
  • 185. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Lee HJ, Rha SY, Chung YE, Shim HS, Kim YJ, Hur J, Hong YJ, Choi BW. Magn Reson Med. 2014 Apr;71(4):1554-8.
  • 186. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK. Eur Urol. 2014 Apr;65(4):723-30.
  • 187. Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee. Kwon KA, Oh SY, Kim HY, Kim HS, Lee HY, Kim TM, Lim HY, Lee NR, Lee HJ, Hong SH, Rha SY. Cancer Res Treat. 2014 Apr;46(2):141-7.
  • 188. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. Br J Cancer. 2014 Apr 15;110(8):1917-22
  • 189. Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case. Hong S, Kim EH, Cho SB, Rha SY. Case Rep Oncol. 2014 May 27;7(2):337-42
  • 190. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Eur Urol. 2014 Jun;65(6):1086-92.
  • 191. Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. Zhang X, Zheng Z, Shin YK, Kim KY, Rha SY, Noh SH, Chung HC, Jeung HC. Pathology. 2014 Jun;46(4):316-24.
  • 192. Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study. Park KS, Kim HS, Cho YJ, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Shin KH, Roh JK. Oncology. 2014 Jun 7;86(5-6):329-335.
  • 193. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. Lee HY, Ahn JB, Rha SY, Chung HC, Park KH, Kim TS, Kim NK, Shin SJ. World J Surg Oncol. 2014 Jul 24;12:232
  • 194. Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. Jang HS, Kim JH, Park KH, Lee JS, Bae JM, Oh BH, Rha SY, Roh MR, Chung KY. Ann Dermatol. 2014 Aug;26(4):485-90.
  • 195. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Kang YK, RhaSY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang YJ. Br J Cancer. 2014 Aug 12;111(4):660-6
  • 196. A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, RhaSY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY. Clin Genitourin Cancer. 2014 Aug;12(4):e127-31.
  • 197. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. J Clin Oncol. 2014 Sep 1;32(25):2765-72.
  • 198. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, RhaSY, Kim JJ, Choueiri TK. Eur Urol. 2014 Oct;66(4):704-10.
  • 199. First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Harshman LC, Kroeger N, RhaSY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK. Clin Genitourin Cancer. 2014 Oct;12(5):335-40.
  • 200. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Park JS, Jeung HC, Rha SY, Ahn JB, Kang B, Chon HJ, Hong MH, Lim S, Yang WI, Nam CM, Chung HC. Cancer Chemother Pharmacol. 2014 Oct;74(4):799-808.
  • 201. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G. Mol Cancer Ther. 2014 Dec;13(12):3074-85.
  • 202. Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. Lee CK, Lee ME, Lee WS, Kim JM, Park KH, Kim TS, Lee KY, Ahn JB, Chung HC, Rha SY. Am J Cancer Res. 2014 Dec 15;5(1):72-86.
  • 203. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, Rha SY. Ann Surg Oncol. 2015 Jan;22(1):224-31
  • 204. Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. Lim SM, Yoo CJ, Han JW, Cho YJ, Kim SH, Ahn JB, Rha SY, Shin SJ, Chung HC, Yang WI, Shin KH, Rho JK, Kim HS. Cancer Res Treat. 2015 Jan;47(1):9-17.
  • 205. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, Rha SY, Kim HS. Oncology. 2015 Jan;88(2):76-85.
  • 206. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. Hong SH, Lee S, Kim HG, Lee HJ, Jung KH, Lee SC, Lee NR, Yun J, Woo IS, Park KH, Kim KH, Kim HY, Rha SY, Byun JH. Gynecol Oncol. 2015 Feb;136(2):212-7.
  • 207. Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. Oncology. 2015 Feb;88(3):147-56.
  • 208. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. Lancet Oncol. 2015 Mar;16(3):293-300.
  • 209. Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report. Joo B, Park MS, Lee SH, Choi HJ, Lim ST, Rha SY, Rachmilevitch I, Lee YH, Suh JS. Yonsei Med J. 2015 Mar;56(2):503-9.
  • 210. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, Koom WS. World J Gastroenterol. 2015 Mar 7;21(9):2711-8
  • 211. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J, Rha SY. BMC Cancer. 2015 Mar 19;15:154.
  • 212. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Clin Genitourin Cancer. 2015 Apr;13(2):e79-85.
  • 213. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY. Clin Genitourin Cancer. 2015 Apr;13(2):150-5.
  • 214. Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients. Rha SY, Park Y, Song SK, Lee CE, Lee J. Eur J Oncol Nurs. 2015 Apr;19(2):174-81.
  • 215. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Park CH, Rha SY, Ahn JB, Shin SJ, Kwon WS, Kim TS, An S, Kim NK, Yang WI, Chung HC. Int J Cancer. 2015 May 15;136(10):2273-83.
  • 216. hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness. Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, Rha SY, Choi EJ, Park JH, Kim JM, Lee JS, Mills GB, Lee HY. Oncogene. 2015 Jun;34(26):3402-12
  • 217. Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. Tamilzhalagan S, Muthuswami M, Periasamy J, Lee MH, Rha SY, Tan P, Ganesan K. Cell Signal. 2015 Jun;27(6):1075-86.
  • 218. Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study. Park S, Noh YH, Rha SY, Kim WH, Cheon JH. Intest Res. 2015 Jul;13(3):274-81.
  • 219. Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. Rha SY, Park Y, Song SK, Lee CE, Lee J. Eur J Oncol Nurs. 2015 Aug;19(4):376-82.
  • 220. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP. Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408.
  • 221. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. Roh MR, Kim JM, Lee SH, Jang HS, Park KH, Chung KY, Rha SY. J Dermatol. 2015 Sep;42(9):881-8.
  • 222. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y. Gastric Cancer. 2015 Oct;18(4):824-32
  • 223. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients who Failed First-line Therapy Containing Darcabazine. Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Cancer Res Treat. 2015 Oct;47(4):781-9.
  • 224. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Gut. 2015 Nov;64(11):1721-31.
  • 225. Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma. Roh MR, Kim JH, Lee SH, Oh SJ, Park KH, Chung KY, Rha SY. Int J Dermatol. 2015 Nov;54(11):e453-7.
  • 226. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Chon HJ, Kim HR, Shin E, Kim C, Heo SJ, Lee CK, Park JK, Noh SH, Chung HC, Rha SY. Ann Surg Oncol. 2015 Nov;22(12):3938-45.
  • 227. Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. Kim HJ, Cho YJ, Kim SH, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Roh JK, Kim KS, Choi YD, Shin KH, Kim HS. Int J Clin Oncol. 2015 Dec;20(6):1226-32.
  • 228. Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS, Rha SY, Chung HC. Ann Surg. 2016 Jan;263(1):96-102.
  • 229. p16 Hypermethylation and KRAS Mutation are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with mCRC. Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Roh JK, Ahn JB. Cancer Res Treat. 2016 Jan;48(1):208-15.
  • 230. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Baiocchi GL, D'Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, Marrelli D, Allum W, Berruti A, Chandramohan SM, Coburn N, Gonzalez-Moreno S, Hoelscher A, Jansen E, Leja M, Mariette C, Meyer HJ, Monig S, Morgagni P, Ott K, Preston S, Rha SY, Roviello F, Sano T, Sasako M, Shimada H, Schuhmacher C, So Bok-Yan J, Strong V, Yoshikawa T, Terashima M, Ter-Ovanesov M, Van der Velde C, Memo M, Castelli F, Pecorelli S, Detogni C, Kodera Y, de Manzoni G. Gastric Cancer. 2016 Jan;19(1):15-20.
  • 231. Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. Noh HS, Hah YS, Ha JH, Kang MY, Zada S, Rha SY, Kang SS, Kim HJ, Park JY, Byun JH, Hahm JR, Shin JK, Jeong SH, Lee YJ, Kim DR. Oncotarget. 2016 Jan 26;7(4):4632-46.
  • 232. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Cancer. 2016 Feb 1;122(3):411-9.
  • 233. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY. Oncotarget. 2016 Feb 16;7(7):8055-66.
  • 234. Cranofacial osteosarcoma: Single institutional experience in Korea. Lim S, Lee S, RhaSY, Rho JK. Asia Pac J Clin Oncol. 2016 Mar;12(1):e149-53.
  • 235. PTEN Methylation Dependent Sinonasal Mucosal Melanoma. Lee SH, Roh MR, Kang B, Park KH, Kim SH, Lee SE, Rha SY. Cancer Res Treat. 2016 Apr;48(2):853-8.
  • 236. A Retrospective Analysis for Patients with HER2 Positive Gastric Cancer who were Treated with Trastuzumab-based Chemotherapy: In the Perspectives of Ethnicity and Histology. Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Cancer Res Treat. 2016 Apr;48(2):553-60.
  • 237. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Lancet. 2016 Apr 16;387(10028):1629-37.
  • 238. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. Kim JH, Lee JS, Kim EJ, Park KH, Kim KH, Yi SH, Kim HS, Cho YJ, Shin KH, Ahn JB, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Noh SH, Rha SY, Kim HS. Oncotarget. 2016 Apr 26;7(17):24549-58.
  • 239. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. Ann Nucl Med. 2016 May;30(4):279-86.
  • 240. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jonsson G, Rha SY, Tsao H. J Invest Dermatol. 2016 May;136(5):1002-11.
  • 241. Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. Kim HR, Kim JH, Rhee Y, Lee H, Song SE, Kim C, Song S, Noh SH, Rha SY. Oncology. 2016 May;90(5):248-54.
  • 242. Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. Park JS, Kim HS, Bae YS, Cheong JH, Rha SY, Noh SH, Kim H. Jpn J Clin Oncol. 2016 Jun;46(6):507-16
  • 243. Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. Oh YJ, Yi SY, Kim KH, Cho YJ, Beum SH, Lee YH, Suh JS, Hur H, Kim KS, Kim SH, Choi YD, Shin KH, Jun HJ, Kim SJ, Lee J, Park SH, Noh SH, Rha SY, Kim HS. J Cancer. 2016 Jun 7;7(9):1174-80.
  • 244. Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho do Y, Lee HY, Rha SY. Yonsei Med J. 2016 Jul;57(4):831-9.
  • 245. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. Lim SM, Kim YN, Park KH, Kang B, Chon HJ, Kim C, Kim JH, Rha SY. BMC Cancer. 2016 Jul 4;16(1):385.
  • 246. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. BMC Cancer. 2016 Jul 8;16:434.
  • 247. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. Oncotarget. 2016 Jul 12;7(28):44608-44620
  • 248. Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. Kim C, Yang H, Park I, Chon HJ, Kim JH, Kwon WS, Lee WS, Kim TS, Rha SY. J Cancer. 2016 Jul 8;7(11):1550-6.
  • 249. Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. Rha SY, Park Y, Song SK, Lee CE, Lee J. Support Care Cancer. 2016 Aug;24(8):3379-89
  • 250. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. J Clin Oncol. 2016 Aug 10;34(23):2728-35.
  • 251. A phase II biomarker-embedded study of lapatinib plus capecitabine as first-line therapy in patients with advanced or metastatic gastric cancer. Labonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ. Mol Cancer Ther. 2016 Sep;15(9):2251-8
  • 252. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, Lee KY, Kim NK, Chung HC. J Cancer Res Clin Oncol. 2016 Sep;142(9):2051-9
  • 253. A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH. Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a000992. doi: 10.1101/mcs.a000992.
  • 254. Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Ooi WF, Xing M, Xu C, Yao X, Ramlee MK, Lim MC, Cao F, Lim K, Babu D, Poon LF, Lin Suling J, Qamra A, Irwanto A, Qu Zhengzhong J, Nandi T, Lee-Lim AP, Chan YS, Tay ST, Lee MH, Davies JO, Wong WK, Soo KC, Chan WH, Ong HS, Chow P, Wong CY, Rha SY, Liu J, Hillmer AM, Hughes JR, Rozen S, Teh BT, Fullwood MJ, Li S, Tan P. Nat Commun. 2016 Sep 28;7:12983. doi: 10.1038/ncomms12983.
  • 255. Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. Kim KH, Kim JH, Lee JY, Kim HS, Heo SJ, Kim JH, Kim HY, Rha SY. Cancer Res Treat 2016 Oct;48(4):1286-1292.
  • 256. ADAR-mediated RNA editing predicts progression and prognosis of Gastric Cancer. Chan TH, Qamra A, Tan KT, Guo J, Yang H, Qi L, Lin JS, Ng VH, Song Y, Hong H, Tay ST, Liu Y, Lee J, Rha SY, Feng Z, So JB, Bin Tean T, Guan YK, Rozen S, Tenen DG, Tan P, Chen L. Gastroenterology. 2016 Oct;151(4):637-650
  • 257. Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. Rha SY, Song SK, Lee CE, Park Y, Lee J. Support Care Cancer. 2016 Nov;24(11):4559-66
  • 258. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Park CK, Park JS, Kim HS, Rha SY, Hyung WJ, Cheong JH, Noh SH, Lee SK, Lee YC, Huh YM, Kim H. Oncotarget. 2016 Nov 1;7(44):72099-72112.
  • 259. Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells. Kim DH, Chang MS, Yoon CJ, Middeldorp JM, Martinez OM, Byeon SJ, Rha SY, Kim SH, Kim YS, Woo JH. Oncotarget. 2016 Dec 13;7(50):82213-82227
  • 260. Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. Chang JS, Kim KH, Keum KC, Noh SH, Lim JS, Kim HS, Rha SY, Lee YC, Hyung WJ, Koom WS. J Surg Oncol. 2016 Dec;114(7):859-864.
  • 261. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. Roh MR, Park KH, Chung KY, Shin SJ, Rha SY, Tsao H. Am J Cancer Res. 2017 Jan 1;7(1):134-138.
  • 262. ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Ki DH, Kim TS, Chung HC. Biochem Pharmacol. 2017 Jan 1;123:73-84. doi: 10.1016/j.bcp.2016.11.005.
  • 263. Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. Kim C, Yoo KH, Kim MH, Chon HJ, Lee SI, Lee HJ, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee SJ, Kim HS. APMIS. 2017 Mar;125(3):223-229. doi: 10.1111/apm.12656.
  • 264. Characterizing the outcomes of metastatic papillary renal cell carcinoma. Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC. Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048.
  • 265. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, Noh SH, Jeung HC. Ann Surg. 2017 May;265(5):946-953. doi: 10.1097/SLA.0000000000001793.
  • 266. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M. Oncotarget. 2017 May 9;8(19):31169-31179. doi: 10.18632/oncotarget.16099.
  • 267. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, Noh SH, Jeung HC. Ann Surg. 2017 May; 265(5):946-953
  • 268. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH, Cho A, Yun M, Choi YD, Rha SY, Kang WJ. Clin Nucl Med. 2017 May;42(5):e235-e241. doi: 10.1097/RLU.0000000000001612.
  • 269. Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. Rha SY, Lee J. Support Care Cancer. 2017 May;25(5):1519-1527. doi: 10.1007/s00520-016-3545-z.
  • 270. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, Choueiri TK. Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2
  • 271. Final overall survival analysis for the phase II RECORD-3 Study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Ann Oncol. 2017 Jun 1:28(6):1339-1345. doi: 10.1093/annonc/mdx075.
  • 272. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. Oncotarget. 2017 Jun 13; 8(24):38389-38398. doi: 10.18632/oncotarget.16409.
  • 273. Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. Chang JS, Kim KH, Yoon HI, Hyung WJ, Rha SY, Kim HS, Lee YC, Lim JS, Noh SH, Koom WS. Br J Surg. 2017 Jun;104(7):877-884.
  • 274. Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Qamra A, Xing M, Padmanabhan N, Kwok JJT, Zhang S, Xu C, Leong YS, Lee Lim AP, Tang Q, Ooi WF, Suling Lin J, Nandi T, Yao X, Ong X, Lee M, Tay ST, Keng ATL, Gondo Santoso E, Ng CCY, Ng A, Jusakul A, Smoot D, Ashktorab H, Rha SY, Yeoh KG, Peng Yong W, Chow PKH, Chan WH, Ong HS, Soo KC, Kim KM, Wong WK, Rozen SG, Teh BT, Kappei D, Lee J, Connolly J, Tan P. Cancer Discov. 2017 Jun;7(6):630-651. doi: 10.1158/2159-8290.CD-16-1022.
  • 277. Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Kwon WS, Rha SY, Jeung HC, Kim TS, Chung HC. Biochem Pharmacol. 2017 Aug 15: 138-173. doi: 10.1016/j.bcp.2017.04.015.
  • 276. Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Jeung HC, Rha SY, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC. Oncol Lett. 2017 Aug;14(2):2385-2392. doi: 10.3892/ol.2017.6438
  • 277. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, Rha SY, Chung HC, Kang SM, Jung M. Oncotarget. 2017 Jun 27;8(37):61837-61845
  • 278. Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. Kim MJ, Kim YS, Oh SY, Lee S, Choi YJ, Seol YM, Park MJ, Kim KH, Park LC, Kang JH, Hwang IG, Lee SI, Lim ST, Kim HS, Lim HY, Rha SY, Kim HJ. Korean J Intern Med. 2016 Apr 6. [Epub ahead of print]
  • 279. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]
  • 280. A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. Kim GM, Reid T, Shin SJ, Rha SY, Ahn JB, Lee SS, Chung HC. Invest New Drugs. 2017 Mar 28. doi: 10.1007/s10637-017-0460-1. [Epub ahead of print]
  • 281. The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. Rha SY, Sohn J, Kim GM, Kim HR, Lee J. Cancer Nurs. Cancer Nurs. 2018 Mar/Apr;41(2):E49-E57.
  • 282. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, Chung HC, Kim KR, Rha SY. BMC Cancer. 2017 Apr 20;17(1):283. doi: 10.1186/s12885-017-3260-2. [Epub ahead of print]
  • 283. Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. Lee J, Yoon HI, Rha SY, Hyung WJ, Lee YC, Lim JS, Kim HS, Koom WS. Clin Transl Oncol. 2017 Clin Transl Oncol. 2017 Oct;19(10):1268-1275.
  • 284. Pazopanib for the Treatment of Non-Clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, Kang JH, Lee S, Rha SY, Lee KH, Kim HY, Lim HY. Cancer Res Treat. 2017 May 22. doi: 10.4143/crt.2016.584. [Epub ahead of print]
  • 285. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. Gastric Cancer. 2018 Mar;21(2):213-224.
  • 286. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT. Clin Cancer Res. 2017 Oct 1;23(19):5981-5992.
  • 287. A randomized phase 2 trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T. Ann Oncol. 2017 Sep 11. doi: 10.1093/annonc/mdx493. [Epub ahead of print]
  • 288. Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Jeung HC, Rha SY, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC. Oncol Lett. 2017 Aug;14(2):2385-2392.
  • 289. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T. Ann Oncol. 2017 Nov 1;28(11):2754-2760.
  • 290. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, Rha SY, Chung HC, Kang SM, Jung M. Oncotarget. 2017 Jun 27;8(37):61837-61845.
  • 291. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Lancet Oncol. 2017 Dec;18(12):1637-1651.
  • 292. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. Lee SH, Kim JE, Jang HS, Park KH, Oh BH, Shin SJ, Chung KY, Roh MR, Rha SY. Cancer Res Treat. 2018 Jan 22. doi: 10.4143/crt.2017.535. [Epub ahead of print]
  • 293. Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY. Exp Mol Med. 2018 Jan 26;50(1):e435. doi: 10.1038/emm.2017.248.
  • 294. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Kim C, Lee CK, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY. Oncotarget. 2017 Dec 9;8(69):113494-113501.
  • 295. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Gastric Cancer. 2018 Jan 25. doi: 10.1007/s10120-018-0794-1. [Epub ahead of print]
  • 296. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Ann Oncol. 2018 Jan 29. doi: 10.1093/annonc/mdx807. [Epub ahead of print]
  • 297. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. Cancer Res Treat. 2018 Feb 5. doi: 10.4143/crt.2018.028. [Epub ahead of print]
  • 298. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS. BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6. [Epub ahead of print]
  • 299. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Gastric Cancer. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print]
  • 300. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY. Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31304. [Epub ahead of print]
  • 301. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YL, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy055. [Epub ahead of print]
  • 302. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP. BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.
  • Correlation of tissue and blood plasminogen activation system in breast cancer
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 150/0 :137-145,2000
  • Effect of telomere and telomerase interactive agents on human tumor and normal cell lines
    CLINICAL CANCER RESEARCH 6/0 :987-993,2000
  • Tissue urokinase-type plasminogen activator receptor levels in breast cancer
    International J Mol Medicine 6/0 :301-305,2000
  • Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biologic effects.
    Mol Cancer Therapeutics 1/0 :103-120,2001
  • Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
    대한암학회지 33/6 :520-526,2001
  • Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 167/2 :215-224,2001
  • Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
    CANCER 91/11 :2016-2025,2001
  • Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
    Cancer Research and Treatment 33/6 :520-526,2001
  • Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.
    Int J Mol Oncol 10/3 :251-256,2002
  • A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane
    CANCER RESEARCH AND TREATMENT 34/4 :274-279,2002
  • Changes of telomerase activity and proliferation by inhibition of reverse transcriptase activity in human cancer cell.
    Cencer Research and Treatment 34/0 :223-233,2002
  • Metastatic model of human gastric cancer by orthotopic transplantation
    대한외과학회지 63/0 :30-34,2002
  • Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
    BRITISH JOURNAL OF SURGERY 89/4 :460-466,2002
  • cDNA microarray를 이용한 HPV-16 E6와 연관된 유전자의 발현 분석.
    대한산부인과학회지(KoreanJournalOfObstetricsAndGynecology) 45/0 :2183-2191,2002
  • cDNA microarray experiment: disign issues in early stage and the need of normalization
    CANCER RESEARCH AND TREATMENT 35/6 :533-540,2003
  • Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray
    Int J Oncology 22/0 :741-750,2003
  • Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer
    MOLECULAR PHARMACOLOGY 56/0 :141-149,2003
  • Infusional 5-flurouracil, leucovorin and docetaxel in advanced gastric cancer
    CANCER RESEARCH AND TREATMENT 35/0 :123-129,2003
  • Infusional Fluorouracil, Etoposide, and Cisplatin(FEP) in Advanced and Relapsed Gastric Cancer
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 26/2 :203-209,2003
  • Paclitaxel and Cisplatin Combination Chemotherapy
    CANCER RESEARCH AND TREATMENT 35/0 :267-273,2003
  • A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma
    YONSEI MEDICAL JOURNAL 44/3 :539-543,2003
  • Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma
    EUROPEAN UROLOGY 44/5 :560-566,2003
  • 국소 진행된 직장암의 수술 전 화학방사선 요법 치료 후 종양반응 분석: 종양체적 변화와 병리조직학적 병기하강과의 상관관계 분석
    대한대장항문학회지(Journal Of The Korean Society Of Coloproctology) 20/5 :296-302,2004
  • In Silico Screening for Angiogenesis-Related Genes in Rat Astrocytes
    GENOMICS & INFORMATICS 2/1 :36-44,2004
  • Phase I and Pharmacokinetic study of the oral fluoropyrimidine S-1 on a Once-Daily-for-28-day schedule in patients with advanced malignancies
    CLINICAL CANCER RESEARCH 10/15 :4913-4921,2004
  • Statistical methods of determining a cut off value between normal and disease groups
    Bulletin of Informatics and Cybernetics 36/ :63-72,2004
  • Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas
    LEUKEMIA & LYMPHOMA 45/9 :1857-1864,2004
  • Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines
    CANCER LETTERS 214/ :215-224,2004
  • The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 13/1 :17-24,2004
  • 직장에 발생한 위장관 간질종양 7예
    대한외과학회지 68/2 :117-122,2005
  • Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 90/3 :215-221,2005
  • 진행된 직장암에서 수술 전 화학 방사선 요법 후 전직장간막절제술의 임상적 고찰: 병리학적 T 병기와 N 병기하강에 따른 임상 결과 분석
    대한외과학회지 68/3 :218-223,2005
  • 직장암에서 전 직장간막 절제술 후 측방절제연이 예후에 미치는 영향
    대한대장항문학회지(Journal Of The Korean Society Of Coloproctology) 21/5 :307-313,2005
  • Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss
    BREAST CANCER RESEARCH AND TREATMENT 93/ :227-236,2005
  • Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray
    CLINICAL CANCER RESEARCH 11/ :79-86,2005
  • Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients
    CLINICAL CANCER RESEARCH 11/ :612-620,2005
  • Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells
    INTERNATIONAL JOURNAL OF CANCER 114/ :484-489,2005
  • Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 16/5 :857-863,2005
  • cDNA 미세배열 비교게놈교잡법 (cDNA microarray-based comparative genomic hybridization)을 이용한 염색체 이상 질환의 최신 고속 산전 유전 진단
    대한산부인과학회지(Korean Journal of Obstetrics and Gynecololy) 48/7 :1621-1634,2005
  • Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction
    FEBS LETTERS 579/ :127-132,2005
  • 제대혈 유래 CD34 양성세포로부터 적혈구 분화유도와 Microarray를 이용한유전자 프로파일 분석
    대한진단검사의학회지 25/6 :457-464,2005
  • Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents
    BIOCHEMICAL PHARMACOLOGY 70/ :13-21,2005
  • Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
    ANNALS OF ONCOLOGY 16/ :1778-1785,2005
  • Systematic analysis of cDNA microarray-based CGH.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 17/ :261-267,2006
  • Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA
    CANCER SCIENCE 97/10 :1082-1092,2006
  • Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
    CANCER RESEARCH AND TREATMENT 38/3 :184-188,2006
  • Significant Gene Selection Using Integrated Microarray Data Set with Batch Effect
    GENOMICS & INFORMATICS 4/3 :110-117,2006
  • Activation of hypoxia-inducible factor-1α is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression
    CLINICAL CANCER RESEARCH 12/21 :6351-6358,2006
  • Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer.
    ONCOLOGY REPORTS 15/ :749-755,2006
  • Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
    PHARMACOGENETICS AND GENOMICS 16/ :429-438,2006
  • 유방암의 전신적 재발로 오인된 톡소플라스마증 1예
    대한내과학회지(korean Journal of medcine) 71/1 :108-113,2006
  • Intermediate dose 5-fluorouracil-induced encephalopathy
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 36/ :55-59,2006
  • A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer
    ONCOLOGY 70/ :63-70,2006
  • A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
    BRITISH JOURNAL OF CANCER 95/ :1637-1641,2006
  • Integrated in silico and biological validation of the blocking effect of C(o)t-1 DNA on microarray-CGH
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 19/ :901-908,2007
  • Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 59/ :295-300,2007
  • Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer
    GENOMICS 89/ :451-459,2007
  • Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 104/ :31-37,2007
  • Bilateral breast cancer: Differential diagnosis using histological and biological parameters
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 37/ :487-492,2007
  • Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-amplified RNA
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20/6 :905-912,2007
  • A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 67/1 :204-210,2007
  • A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
    BRITISH JOURNAL OF CANCER 97/ :458-463,2007
  • Role of(18)F-Fluorodeoxyglucose positron Emission Tomography in detecting Extrahepatic Metastasisin pretreatment staging of hin pretreatment staging of hepatocellular carcinoma
    ONCOLOGY 72/S1 :104-110,2007
  • Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
    ONCOLOGIST 12/5 :543-554,2007
  • Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
    ACTA ONCOLOGICA 46/4 :547-549,2007
  • Gastrointestinal stromal tumor of the rectum: An analysis of seven cases
    SURGERY TODAY 37/6 :455-459,2007
  • Whole genome analysis for liver metastasis gene signatures in colorectal cancer
    INTERNATIONAL JOURNAL OF CANCER 121/ :2005-2012,2007
  • Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute
    JOURNAL OF SURGICAL ONCOLOGY 95/ :461-468,2007
  • An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients
    ONCOLOGIST 12/ :622-630,2007
  • Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents
    ONCOLOGY REPORTS 18/ :593-599,2007
  • A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 59/ :313-320,2007
  • Molecular basis of the differences between normal and tumor tissues of gastric cancer
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1772/ :1033-1040,2007
  • An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions
    Cancer Research and Treatment 39/2 :74-81,2007
  • The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation
    ONCOGENE 26/6 :934-944,2007
  • Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia
    YONSEI MEDICAL JOURNAL 48/2 :171-175,2007
  • The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas
    LABORATORY INVESTIGATION 87/7 :644-650,2007
  • Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization
    BMC GENOMICS 8/ :749-754,2007
  • Novel and simple transformation algorithm for combining microarray data sets
    BMC BIOINFORMATICS 8/ :310-316,2007
  • Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: A 15-year follow-up study at a single korean institute
    ANNALS OF SURGICAL ONCOLOGY 14/ :2730-2737,2007
  • A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and ...
    BREAST CANCER RESEARCH AND TREATMENT 39/3 :134-137,2007
  • Variation of the 3 ` telomeric overhang lengths in human cells
    Cancer Letters 264/ :107-118,2008
  • Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
    Breast Cancer Research And Treatment 108/ :241-250,2008
  • Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
    Radiotherapy And Oncology 87/ :361-366,2008
  • Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
    Cancer Chemotherapy And Pharmacology 61/ :157-165,2008
  • The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
    Cancer Chemotherapy And Pharmacology 61/ :75-81,2008
  • A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer
    Cancer Chemotherapy And Pharmacology 61/ :315-321,2008
  • Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A : U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
    Annals Of Oncology 19/ :520-526,2008
  • Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases
    Annals Of Oncology 19/ :1146-1153,2008
  • Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions
    Bmc Bioinformatics 9/ :-,2008
  • Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene
    Cancer Research 68/ :4277-4286,2008
  • OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation
    PLoS One 3/8 :-,2008
  • SNPAnalyzer 2.0: A web-based integrated workbench for linkage disequilibrium analysis and association analysis
    Bmc Bioinformatics 9/0 :0-0,2008
  • S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer
    The Korean Journal Of Internal Medicine 23/1 :37-41,2008
  • Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma
    Molecular Cancer Research 6/10 :1554-1566,2008
  • Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer
    Archives Of Surgery 143/ :1091-1097,2008
  • Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
    Annals Of Oncology 19/6 :1135-1140,2008
  • Disease Prediction Using Ranks of Gene Expressions
    Genomics & Informatics 6/3 :136-141,2008
  • Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer
    Cancer Letters 270/2 :269-276,2008
  • In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer
    Genomics 93/ :52-61,2009
  • Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
    Annals Of Oncology 20/2 :272-277,2009
  • The Effect of Spleen-Preserving Lymphadenectomy on Surgical Outcomes of Locally Advanced Proximal Gastric Cancer
    Journal Of Surgical Oncology 99/ :275-280,2009
  • Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma
    Journal Of Gastroenterology And Hepatology 24/3 :475-479,2009
  • Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery
    International Journal Of Oncology 34/ :837-846,2009
  • Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer
    International Journal Of Oncology 34/3 :787-796,2009
  • Subtelomeric DNA methylation and telomere length in human cancer cells
    Cancer Letters 281/1 :82-91,2009
  • Prediction of recurrence of early gastric cancer after curative resection
    Annals Of Surgical Oncology 16/7 :1896-1902,2009
  • Identification of significant regional genetic variations using continuous CNV values in aCGH data
    Genomics 94/3 :317-323,2009
  • A weighted sample size for microarray datasets that considers the variability of variance and multiplicity
    Journal Of Bioscience And Bioengineering 108/3 :252-258,2009
  • Promoter Methylation of the Wnt/beta-Catenin Signaling Antagonist Dkk-3 Is Associated With Poor Survival in Gastric Cancer
    Cancer 115/1 :49-60,2009
  • DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers
    British Journal Of Cancer 100/4 :663-669,2009
  • Phospholipase c delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer
    Oncogene 28/26 :2466-2475,2009
  • Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 65/1 :167-175,2009
  • oncogenic pathway combinations predict clinical prognosis in gastric cancer
    Plos Genetics 5/ :e1000676-,2009
  • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
    Cancer Research And Treatment 41/2 :67-72,2009
  • Prognosis of pN3 stage gastric cancer
    Cancer Research And Treatment 41/2 :73-79,2009
  • clinical value of ezrin expression in primary osteosarcoma
    Cancer Research And Treatment 41/3 :138-144,2009
  • Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma
    Annals Of Oncology 20/4 :780-787,2009
  • Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer
    Journal Of Surgical Oncology 100/6 :459-465,2009
  • A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status
    Oncology 77/6 :349-357,2009
  • Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
    Cancer Research And Treatment 41/4 :196-204,2009
  • Changes of Telomerase Activity by Alternative Splicing of Full-Length and beta Variants of hTERT in Breast Cancer Patients
    Oncology Research 18/5-6 :213-220,2009
  • Prognostic index reflecting genetic alteration related to disease-free time for gastric cancer patient
    Oncology Reports 22/2 :421-431,2009
  • Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction
    Yonsei Medical Journal 50/2 :296-299,2009
  • Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients
    Cancer Letters 288/1 :124-132,2010
  • Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m(2) bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40/1 :29-35,2010
  • Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy
    Oncology Reports 23/ :271-278,2010
  • A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer
    American Journal of Clinical Oncology-Cancer Clinical Trials 33/1 :56-60,2010
  • Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/12 :1901-1913,2010
  • The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/ :517-526,2010
  • Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
    Radiotherapy And Oncology 95/3 :303-307,2010
  • Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/3 :387-394,2010
  • Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/4 :797-805,2010
  • A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
    Investigational New Drugs 28/5 :650-658,2010
  • Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia
    Cancer Genetics and Cytogenetics 201/2 :73-80,2010
  • Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
    CANCER SCIENCE 101/10 :2200-2206,2010
  • Identification of Novel Gastric Cancer-Associated CNVs by Integrated Analysis of Microarray
    Journal Of Surgical Oncology 102/5 :454-461,2010
  • Wernicke’s Encephalopathy in Advanced Gastric Cancer
    Cancer Research and Treatment 42/2 :77-81,2010
  • Green Tea Consumption and Stomach Cancer Risk: A Meta-Analysis
    Korean Journal Of Epidemiology(한국역학회지) 32/ :1-8,2010
  • The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
    Annals of Surgical Oncology 17/12 :3259-3268,2010
  • Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
    Cancer Research and Treatment 42/3 :180-184,2010
  • Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
    Cancer Research and Treatment 42/4 :217-224,2010
  • Kidney Cancer Working Group Report
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40/suppl1 :i51-i56,2010
  • Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
    International Journal Of Hyperthermia 26/4 :305-315,2010
  • Brain metastases from colorectal carcinoma: prognostic factors and outcome
    JOURNAL OF NEURO-ONCOLOGY 101/ :49-55,2011
  • Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells
    BREAST CANCER RESEARCH AND TREATMENT 125/1 :55-63,2011
  • Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis
    ONCOLOGY REPORTS 25/3 :717-727,2011
  • Prevalence and associated factors of psychological distress among Korean cancer patients
    GENERAL HOSPITAL PSYCHIATRY 33/3 :246-252,2011
  • Gadoxetate Disodium-Enhanced Hepatobiliary Phase MRI of Hepatocellular Carcinoma: Correlation With Histological Characteristics
    AMERICAN JOURNAL OF ROENTGENOLOGY 197/2 :399-405,2011
  • Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer
    SUPPORTIVE CARE IN CANCER 19/7 :971-978,2011
  • A Randomized Phase 2 Study of Docetaxel and S-1 Versus Docetaxel and Cisplatin in Advanced Gastric Cancer With an Evaluation of SPARC Expression for Personalized Therapy
    CANCER 117/10 :2050-2057,2011
  • Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer
    ANTI-CANCER DRUGS 22/8 :801-810,2011
  • A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
    ONCOLOGY 80/1-2 :142-150,2011
  • Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
    ONCOLOGY 80/5-6 :395-405,2011
  • CD44-SLC1A2 Gene Fusions in Gastric Cancer
    SCIENCE TRANSLATIONAL MEDICINE 3/77 :1-11,2011
  • Treatment of recurrent hepatocellular carcinoma after liver transplantation
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 7/3 :258-269,2011
  • Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 68/0 :991-999,2011
  • Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity
    ONCOLOGY 80/1-2 :107-117,2011
  • Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 2/ :685-693,2011
  • Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy
    GASTROENTEROLOGY 141/2 :476-485,2011
  • Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41/ :1344-1350,2011
  • A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures
    PLOS GENETICS 7/12 :-,2011
  • MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer
    HEPATO-GASTROENTEROLOGY 58/112 :2015-2019,2011
  • Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis
    ONCOLOGY 81/3-4 :175-183,2011
  • Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer
    CLINICAL CANCER RESEARCH 17/9 :2657-2667,2011
  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    JOURNAL OF CLINICAL ONCOLOGY 29/30 :3968-3976,2011
  • Systematic Analyses of Genes Associated with Radiosensitizing Effect by Celecoxib, a Specific Cyclooxygenase-2 Inhibitor
    JOURNAL OF RADIATION RESEARCH 52/6 :752-765,2011
  • Methylation Status of Lamin A/C in Gastric Cancer Cell Lines
    HEPATO-GASTROENTEROLOGY 59/116 :1313-1318,2012
  • Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer
    INTERNATIONAL JOURNAL OF ONCOLOGY 40/3 :889-898,2012
  • Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
    CANCER 118/3 :729-739,2012
  • A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer
    INVESTIGATIONAL NEW DRUGS 30/ :357-363,2012
  • A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
    EUROPEAN JOURNAL OF CANCER 48/ :518-526,2012
  • A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/ :672-680,2012
  • Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma
    EXPERIMENTAL AND MOLECULAR PATHOLOGY 92/2 :236-242,2012
  • External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
    ANNALS OF ONCOLOGY 23/ :361-U336,2012
  • A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer
    GYNECOLOGIC ONCOLOGY 126/3 :357-363,2012
  • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
    GUT 61/5 :673-684,2012
  • Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
    CANCER 118/5 :1252-1259,2012
  • Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 69/3 :635-642,2012
  • Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
    Cancer Research and Treatment 44/1 :43-49,2012
  • Body fluid MMP-2 as a putative biomarker in metastatic breast cancer
    ONCOLOGY LETTERS 3/3 :699-703,2012
  • Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes
    NATURE GENETICS 44/5 :570-574,2012
  • Phase II study of the safety and efficacy of temsirolimus in east asian patients with advanced renal cell carcinoma
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 42/9 :836-844,2012
  • Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
    PLOS ONE 7/9 :e45127-e45127,2012
  • Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeuti
    JOURNAL OF CLINICAL ONCOLOGY 30/27 :3361-3367,2012
  • Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: A population-based study
    LANCET ONCOLOGY 13/9 :927-935,2012
  • A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012
  • Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: Implications for postoperative radiotherapy
    RADIOTHERAPY AND ONCOLOGY 104/3 :367-373,2012
  • Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
    BMC CANCER 12/1 :471-471,2012
  • Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
    BMC GENOMICS 13/348 :-,2012
  • Quantitative Analysis of ERK Signaling Inhibition in Colon Cancer Cell Lines Using Phospho-Specific Flow Cytometry
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 34/ :309-316,2012
  • EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
    YONSEI MEDICAL JOURNAL 53/6 :1128-1135,2012
  • An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
    EUROPEAN JOURNAL OF CANCER 48/3 :324-332,2012
  • Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
    BMC CANCER 12/322 :1-11,2012
  • Identifying genes related to radiation resistance in oral squamous cell carcinoma cell lines
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY 42/2 :169-176,2013
  • Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
    INVESTIGATIONAL NEW DRUGS 31/1 :1-13,2013
  • Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
    JOURNAL OF RADIATION RESEARCH 54/1 :52-60,2013
  • Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1.
    JOURNAL OF GENERAL VIROLOGY 94/Pt3 :497-506,2013
  • Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice
    MELANOMA RESEARCH 23/2 :114-124,2013
  • Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer.
    JOURNAL OF CLINICAL ONCOLOGY 31/6 :731-737,2013
  • Increased Alternative Lengthening of Telomere Phenotypes of Telomerase-negative Immortal Cells upon Trichostatin ? A Treatment
    ANTICANCER RESEARCH 33/3 :821-830,2013
  • Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer
    GUT 62/1 :22-33,2013
  • Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
    UROLOGY 81/1 :143-149,2013
  • Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis
    BRITISH JOURNAL OF CANCER 108/1 :39-48,2013
  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
    LANCET ONCOLOGY 14/2 :141-148,2013
  • Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 31/5 :1202-1208,2013
  • Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study
    JOURNAL OF SURGICAL ONCOLOGY 107/6 :613-618,2013
  • Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
    ANNALS OF ONCOLOGY 24/4 :1026-1031,2013
  • The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
    YONSEI MEDICAL JOURNAL 54/4 :865-874,2013
  • Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
    ANNALS OF SURGICAL ONCOLOGY 20/8 :2615-2624,2013
  • Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
    BMC CANCER 13/394 :1-7,2013
  • Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
  • Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells
    ANTICANCER RESEARCH 33/6 :2499-2508,2013
  • Changing treatment patterns in elderly patients with resectable colon cancer
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 9/3 :265-272,2013
  • Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
    YONSEI MEDICAL JOURNAL 54/4 :854-864,2013
  • Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation
    RADIOTHERAPY AND ONCOLOGY 108/1 :72-77,2013
  • Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/ :825-835,2013
  • Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/4 :853-860,2013
  • PIK3CA Mutations in Hepatocellular Carcinoma in Korea
    YONSEI MEDICAL JOURNAL 54/4 :883-887,2013
  • Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
    CANCER 119/16 :2999-3006,2013
  • Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide
    INVESTIGATIONAL NEW DRUGS 31/6 :1602-1608,2013
  • Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study
    JOURNAL OF CLINICAL PATHOLOGY 67/1 :33-39,2014
  • Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: Correlation with histological microvessel density
    MAGNETIC RESONANCE IN MEDICINE 71/4 :1554-1558,2014
  • Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study
    ONCOLOGY 86/5-6 :329-335,2014
  • Ifosfamide-induced Fanconi syndrome with diabetes insipidus
    KOREAN JOURNAL OF INTERNAL MEDICINE 29/2 :246-249,2014
  • Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer
    PATHOLOGY 46/4 :316-324,2014
  • Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure
    ANNALS OF DERMATOLOGY 26/4 :485-490,2014
  • High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
    WORLD JOURNAL OF SURGICAL ONCOLOGY 12/- :232-238,2014
  • Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
  • Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma
    JOURNAL OF CLINICAL ONCOLOGY 32/25 :2765-2772,2014
  • Kaposi's varicelliform-like eruption in a patient treated with everolimus for metastatic renal cell carcinoma: Report of a rare case
    Case Reports in Oncology 7/2 :337-342,2014
  • Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
    CANCER RESEARCH AND TREATMENT 46/2 :141-147,2014
  • Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
    EUROPEAN JOURNAL OF CANCER 50/4 :746-752,2014
  • A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
    BRITISH JOURNAL OF CANCER 111/4 :660-666,2014
  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    EUROPEAN UROLOGY 66/4 :704-710,2014
  • First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
    BRITISH JOURNAL OF CANCER 110/8 :1917-1922,2014
  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial
    LANCET ONCOLOGY 15/3 :286-296,2014
  • Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients
    BRITISH JOURNAL OF CANCER 110/6 :1433-1437,2014
  • Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
    INTERNATIONAL JOURNAL OF ONCOLOGY 44/1 :5-16,2014
  • Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
    ANNALS OF ONCOLOGY 25/1 :149-154,2014
  • A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma
    CLINICAL GENITOURINARY CANCER 12/4 :e127-e131,2014
  • First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium
    CLINICAL GENITOURINARY CANCER 12/5 :335-340,2014
  • The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression.
    MOLECULAR CANCER THERAPEUTICS 13/12 :3074-3085,2014
  • The Metalloprotease ADAMTS8 Displays Antitumor Properties through Antagonizing EGFR-MEK-ERK Signaling and Is Silenced in Carcinomas by CpG Methylation
    MOLECULAR CANCER RESEARCH 12/2 :228-238,2014
  • The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium
    EUROPEAN UROLOGY 65/4 :723-730,2014
  • Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
    EUROPEAN UROLOGY 65/3 :577-584,2014
  • Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy
    EUROPEAN UROLOGY 65/6 :1086-1092,2014
  • PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
    ONCOLOGY 88/2 :76-85,2015
  • Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
  • Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
    CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
  • Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer
    WORLD JOURNAL OF GASTROENTEROLOGY 21/9 :2711-2718,2015
  • PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity
    INTERNATIONAL JOURNAL OF CANCER 136/10 :2273-2283,2015
  • Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer
    AMERICAN JOURNAL OF CANCER RESEARCH 5/1 :72-86,2015
  • Pain Palliation in Patients with Bone Metastases Using Magnetic Resonance-Guided Focused Ultrasound with Conformal Bone System: A Preliminary Report
    YONSEI MEDICAL JOURNAL 56/2 :503-509,2015
  • Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: A retrospective case series
    BMC CANCER 15/154 :1-7,2015
  • Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study
    Intestinal research 13/3 :274-281,2015
  • Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation
    JOURNAL OF DERMATOLOGY 42/9 :881-888,2015
  • Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
    ONCOLOGY 88/3 :147-156,2015
  • Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 76/2 :397-408,2015
  • Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates
    EUROPEAN JOURNAL OF ONCOLOGY NURSING 19/4 :376-382,2015
  • Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer
    CELLULAR SIGNALLING 27/6 :1075-1086,2015
  • The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: A population-based study
    LANCET ONCOLOGY 16/3 :293-300,2015
  • Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium
    CLINICAL GENITOURINARY CANCER 13/2 :150-155,2015
  • Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium
    CLINICAL GENITOURINARY CANCER 13/2 :79-85,2015
  • Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.
    GUT 64/11 :1721-1731,2015
  • Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10
    GYNECOLOGIC ONCOLOGY 136/2 :212-217,2015
  • Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
    GASTRIC CANCER 18/4 :824-832,2015
  • Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma
    INTERNATIONAL JOURNAL OF DERMATOLOGY 54/11 :e453-e457,2015
  • Leiomyosarcoma: investigation of prognostic factors for risk-stratification model
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20/6 :1226-1232,2015
  • The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/12 :3938-3945,2015
  • Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
    CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
  • Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients
    EUROPEAN JOURNAL OF ONCOLOGY NURSING 19/2 :174-181,2015
  • HTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness
    ONCOGENE 34/26 :3402-3412,2015
  • 골종양의 항암치료에 대한 전략
    대한정형외과학회지 50/6 :438-443,2015
  • Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
    ANNALS OF SURGERY 263/1 :96-102,2016
  • Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell
    CANCER 122/3 :411-419,2016
  • Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference
    GASTRIC CANCER 19/1 :15-20,2016
  • p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
    CANCER RESEARCH AND TREATMENT 48/1 :208-215,2016
  • PTEN Methylation Dependent Sinonasal Mucosal Melanoma
    CANCER RESEARCH AND TREATMENT 48/2 :853-858,2016
  • Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy
    ONCOLOGY 90/5 :248-254,2016
  • Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma
    YONSEI MEDICAL JOURNAL 57/4 :831-839,2016
  • Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival
    JOURNAL OF INVESTIGATIVE DERMATOLOGY 136/5 :1002-1011,2016
  • Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
    ONCOTARGET 7/7 :8055-8066,2016
  • Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience.
    JOURNAL OF CANCER 7/9 :1174-1180,2016
  • Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
    ONCOTARGET 7/17 :24549-24558,2016
  • Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
    ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
  • Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients
    BMC CANCER 16/1 :385-,2016
  • Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis
    JOURNAL OF CANCER 7/11 :1550-1556,2016
  • Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
    BMC CANCER 16/434 :1-7,2016
  • Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
    ONCOTARGET 7/28 :44608-44620,2016
  • High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 142/9 :2051-2059,2016
  • Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity
    ONCOTARGET 7/4 :4,632-4,646,2016
  • Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 46/6 :507-516,2016
  • Cranofacial osteosarcoma: Single institutional experience in Korea
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 12/1 :e149-e153,2016
  • A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
    CANCER RESEARCH AND TREATMENT 48/2 :553-560,2016
  • Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients
    SUPPORTIVE CARE IN CANCER 24/8 :3,379-3,389,2016
  • Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms
    SUPPORTIVE CARE IN CANCER 24/11 :4559-4566,2016
  • A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
    MOLECULAR CANCER THERAPEUTICS 15/9 :2,251-2,258,2016
  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
    LANCET 387/10028 :1,629-1,637,2016
  • ADAR-mediated RNA editing predicts progression and prognosis of Gastric Cancer.
    GASTROENTEROLOGY 151/4 :637-650,2016
  • Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
    CANCER RESEARCH AND TREATMENT 48/4 :1,286-1,292,2016
  • Recursive Partition Analysis of Peritoneal and Systemic Recurrence in Patients With Gastric Cancer Who Underwent D2 Gastrectomy: Implications for Neoadjuvant Therapy Consideration
    JOURNAL OF SURGICAL ONCOLOGY 114/7 :859-864,2016
  • Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm
    ONCOTARGET 7/44 :72,099-72,112,2016
  • A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE 2/5 :a000992-,2016
  • Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity.
    NATURE COMMUNICATIONS 7/12983 :1-17,2016
  • Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells
    ONCOTARGET 7/50 :82,213-82,227,2016
  • Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
    JOURNAL OF CLINICAL ONCOLOGY 34/23 :2,728-2,735,2016
  • ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition
    BIOCHEMICAL PHARMACOLOGY 123/ :73-84,2017
  • Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma
    APMIS 125/3 :223-229,2017
  • Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients
    AMERICAN JOURNAL OF CANCER RESEARCH 7/1 :134-138,2017
  • Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    CLINICAL NUCLEAR MEDICINE 42/5 :e235-e241,2017
  • Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
    ANNALS OF SURGERY 265/5 :946-953,2017
  • Prevalence and prognostic implications of psychological distress in patients with gastric cancer
    BMC CANCER 17/1 :283-,2017
  • Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    ONCOTARGET 8/19 :31,169-31,179,2017
  • Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines
    BIOCHEMICAL PHARMACOLOGY 138/ :163-173,2017
  • Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
    ONCOTARGET 8/24 :38,389-38,398,2017
  • Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer
    ONCOLOGY LETTERS 14/2 :2,385-2,392,2017
  • Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer
    BRITISH JOURNAL OF SURGERY 104/7 :877-884,2017
  • Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    ONCOTARGET 8/37 :61,837-61,845,2017
  • Characterizing the outcomes of metastatic papillary renal cell carcinoma
    CANCER MEDICINE 6/5 :902-909,2017
  • Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life
    SUPPORTIVE CARE IN CANCER 25/5 :1,519-1,527,2017
  • Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma
    CLINICAL GENITOURINARY CANCER 15/3 :403-410,2017
  • Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
    ANNALS OF ONCOLOGY 28/6 :1,339-1,345,2017
  • Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma
    CANCER DISCOVERY 7/6 :630-651,2017
  • Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer
    CLINICAL & TRANSLATIONAL ONCOLOGY 19/10 :1,268-1,275,2017
  • A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
    CLINICAL CANCER RESEARCH 23/19 :5,981-5,992,2017
  • A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
    INVESTIGATIONAL NEW DRUGS 35/6 :773-781,2017
  • PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
    ONCOTARGET 8/69 :113,494-113,501,2017
  • Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
    BMC CANCER 18/1 :158-165,2018
  • The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control.
    CANCER NURSING 41/2 :49-57,2018
  • Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin
    EXPERIMENTAL AND MOLECULAR MEDICINE 50/1 :435-445,2018
  • Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
    KOREAN JOURNAL OF INTERNAL MEDICINE 33/2 :383-390,2018
  • Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor
    INTERNATIONAL JOURNAL OF CANCER 143/1 :151-159,2018
  • The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
    GASTRIC CANCER 21/2 :213-224,2018
  • A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
    AAPS JOURNAL 20/4 :72-87,2018
  • Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
    ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
  • Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
    GASTRIC CANCER 21/5 :819-830,2018
  • Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
    CANCER RESEARCH AND TREATMENT 50/4 :1,378-1,387,2018
  • MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
    JOURNAL OF SURGICAL ONCOLOGY 117/8 :1,679-1,686,2018
  • Reconsideration of sample size and power calculation for overall survival in cancer clinical trials
    Contemporary clinical trials communications 12/ :90-91,2018
  • BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 19/10 :3,164-3,178,2018
  • CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer
    YONSEI MEDICAL JOURNAL 59/5 :588-594,2018
  • Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
    CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
  • Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    ANTICANCER RESEARCH 38/11 :6,171-6,180,2018
  • Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 22/12 :5,899-5,908,2018
  • Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
    BMC CANCER 18/1 :1116-1127,2018
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
    BRITISH JOURNAL OF CANCER 119/6 :663-669,2018
  • Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
    Cancers 10/11 :455-472,2018
  • S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
    CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
  • The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.
    GASTRIC CANCER 22/1 :113-122,2019

라선영

진료철학
진료의 시작은 환자와의 만남에서부터 입니다. 의사-환자의 관계 이전에 사람과 사람간의 관계로 만나고자 합니다. 장기별로 병만을 찾아 치료하려 하지 않고, 환자 안에서의 질병을 이해하고 도와줄 수 있는 방법을 찾아 하나씩 하나씩 해결하고자 합니다. 어떤 질병보다도 암환자에게는 의사의 관심어린 말 한마디, 눈길 한번 손길 한번이 큰 힘이 되는 것을 알고 있습니다. 아직까지 현대의학과 사람의 힘으로 한계가 있지만, 의료진과 환자와 가족이 한 마음이 되어 노력하면 감사드릴 수 있는 결과를 얻을 수 있으리라 믿습니다.

하지만 실질적인 준비 없이 마음만으로 환자가 치료되지는 않습니다. 정확한 정보와 최신 지식을 얻기 위해 계속 정진하고, 현재 해결하지 못하는 문제점들을 정복하기 위한 연구에도 지속적인 노력을 다하고자 합니다. 기초연구와 여러분들의 협조를 기반으로 하는 임상연구를 통해 더 많은 양질의 치료 기회를 마련하겠습니다.

마지막으로, 의사로서 자긍심을 가지고 자신의 선택과 결정에 후회하지 않고, 매 순간 자신을 돌아보며 지내는 의과학자 이고자 합니다. 누구를 위한 진료이고 연구인지를 항상 생각하며 자만하지 않고 다른 전문가들의 의견들을 열린 마음으로 받아들이고 상의할 수 있는 종양내과 전문가이고자 합니다.

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보